Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)

Next Previous
Trial Profile

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HMB VWF (Primary)
  • Indications Von Willebrand disease
  • Focus Adverse reactions; First in man
  • Sponsors Hemab

Most Recent Events

  • 27 Feb 2025 According to a Hemab media release,The study is actively enrolling participants, with interim data anticipated later this year.
  • 27 Feb 2025 According to a Hemab media release, Dr. Ulrike Lorch is the Principal Investigator of the trial.
  • 27 Feb 2025 According to a Hemab media release, the first participant with Von Willebrand Disease (VWD) has been dosed in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top